# Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Canonical URL: https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-three-presentations-at-the-2026-asgct-annual-meeting-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and-autoimmune-diseases
Ticker: FATE
Company: Fate Therapeutics
Source: Fate Therapeutics
Published: 2026-05-04 13:00 EST
Original Source URL: https://ir.fatetherapeutics.com
## Summary

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

## Article Body
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,
## Recent Company News
- 2026-06-01 12:30 EST — [Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-clinical-data-for-ft836-at-the-american-society-of-cancer-oncology-annual-meeting) — Source: Fate Therapeutics
- 2026-05-21 12:30 EST — [Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases](https://biopharmsignal.com/news/FATE/fate-therapeutics-announces-presentations-at-2026-asco-and-eular-annual-meetings-highlighting-off-the-shelf-car-t-cell-therapy-pipeline-for-cancer-and-autoimmune-diseases) — Source: Fate Therapeutics
- 2026-05-13 12:30 EST — [Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Fate Therapeutics
- 2026-05-11 12:30 EST — [Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-ft819-clinical-activity-in-sle-without-the-use-of-conditioning-chemotherapy-at-the-2026-asgct-annual-meeting) — Source: Fate Therapeutics
- 2026-05-05 12:30 EST — [Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819](https://biopharmsignal.com/news/FATE/fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ft819) — Source: Fate Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)